Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
Current Oncology · 24.12.2024 · 32 (1) · 2
DOI: 10.3390/curroncol32010002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 24.12.2024. Verfasst von Jenna Shaw und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 2Y9, Canada. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require close monitoring and prompt management. This retrospective review aimed to describe the characteristics of adult patients with r/r LBCL deemed eligible to receive CAR T-cell therapy with axicabtagene ciloleucel in NS between January 2022 and June 2024, the toxicities experienced and toxicity management, hospital visits and intensive care unit (ICU) admissions, the utilization of toxicity management guidelines, and general efficacy outcomes. Twenty-seven patients received axicabtagene ciloleucel. All patients experienced CRS (7.4% grade ≥ 3), and 55.6% developed ICANS (25.9% grade ≥ 3). The median hospital stay was 18 days, with 40.7% requiring ICU admission. There was one treatment-related mortality. Most CRS (85.2%) and ICANS (80.0%) cases were managed according to the guidelines. By day +100, the best objective response rate was 81.5% (44.4% complete responses). Patients who received CAR T-cell therapy in NS, Canada, experienced comparable toxicities and efficacy to those reported in pivotal clinical trials and other real-world experiences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 2Y9, Canada.
- QEII Health Sciences Centre, Division of Hematology and Hematologic Oncology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
- Cell Therapy and Transplant Program, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 2Y9, Canada.
ORCID-Profile: Jenna Shaw, Laura V Minard
Zitieren
APA
Shaw, J., Elsawy, M., Nielsen, R., Harrigan, A. M., DiCostanzo, T. T., & Minard, L. V. (2024). Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada. Current Oncology, 32(1), 2. https://doi.org/10.3390/curroncol32010002
Vancouver
Shaw J, Elsawy M, Nielsen R, Harrigan AM, DiCostanzo TT, Minard LV. Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada. Current Oncology. 2024;32(1):2. doi:10.3390/curroncol32010002
BibTeX
@article{Shaw2024,
author = {Shaw, Jenna and Elsawy, Mahmoud and Nielsen, Rachel and Harrigan, Amye Michelle and DiCostanzo, Tara T and Minard, Laura V},
title = {Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada},
journal = {Current Oncology},
year = {2024},
volume = {32},
number = {1},
pages = {2},
doi = {10.3390/curroncol32010002}
}
EUVIMED